For patients who have spent years managing unpredictable and debilitating autoimmune conditions like lupus, the findings ...

Researchers at UC San Francisco have now developed a way to reprogram these cancer-fighting cells directly inside the body. This new method could remove the need for external manufacturing, ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biologyVANCOUVER, British ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

Genetically engineered immune cells known as CAR-T cells might be able to slow the progress of the neurodegenerative condition amyotrophic lateral sclerosis (ALS) by killing off rogue immune cells in ...

Chimeric antigen receptor (CAR) T-cell therapy has cleared another hurdle on the path to potentially becoming a viable treatment option for people with severe autoimmune diseases, following the recent ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical testing, is focused on B cell–driven autoimmune diseases. Eli Lilly has long ...

LOS ANGELES (KABC) -- For decades, treatments for lupus, which affects 1.5 million Americans, have been few and far between. The condition affects mainly women and can be debilitating. Now, a ...